Literature DB >> 21910081

Heart sphingolipids in health and disease.

Marcin Baranowski1, Jan Górski.   

Abstract

In recent years, the role of sphingolipids in physiology and pathophysiology of the heart attracted much attention. Ceramide was found to be involved in the pathogenesis of cardiac dysfunction in animal models of ischemia/reperfusion injury, Type 2 diabetes and lipotoxic cardiomyopathy. On the other hand, another member of this lipid family, namely sphingosine-1-phosphate, has been shown to possess potent cardioprotective properties. This chapter provides a review of the role of ceramide and other bioactive sphingolipids in physiology and pathophysiology of the heart. We describe the role of PPARs and exercise in regulation of myocardial sphingolipid metabolism. We also summarize the present state of knowledge on the involvement of ceramide and sphingosine-1-phosphate in the development and prevention of ischemia/reperfusion injury of the heart. In the last section of this chapter we discuss the evidence for a role of ceramide in myocardial lipotoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910081     DOI: 10.1007/978-1-4614-0650-1_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  19 in total

1.  Lactosylceramide contributes to mitochondrial dysfunction in diabetes.

Authors:  Sergei A Novgorodov; Christopher L Riley; Jin Yu; Jarryd A Keffler; Christopher J Clarke; An O Van Laer; Catalin F Baicu; Michael R Zile; Tatyana I Gudz
Journal:  J Lipid Res       Date:  2016-02-21       Impact factor: 5.922

2.  Ceramide signaling in the coronary microcirculation: a double-edged sword?

Authors:  Brian R Weil; John M Canty
Journal:  Circ Res       Date:  2014-08-15       Impact factor: 17.367

3.  Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk.

Authors:  Rozenn N Lemaitre; Paul N Jensen; Andrew Hoofnagle; Barbara McKnight; Amanda M Fretts; Irena B King; David S Siscovick; Bruce M Psaty; Susan R Heckbert; Dariush Mozaffarian; Nona Sotoodehnia
Journal:  Circ Heart Fail       Date:  2019-07-12       Impact factor: 8.790

Review 4.  Sphingolipids and mitochondrial apoptosis.

Authors:  Gauri A Patwardhan; Levi J Beverly; Leah J Siskind
Journal:  J Bioenerg Biomembr       Date:  2016-04       Impact factor: 2.945

5.  Ceramide-Protein Interactions Modulate Ceramide-Associated Lipotoxic Cardiomyopathy.

Authors:  Stanley M Walls; Anthony Cammarato; Dale A Chatfield; Karen Ocorr; Greg L Harris; Rolf Bodmer
Journal:  Cell Rep       Date:  2018-03-06       Impact factor: 9.423

Review 6.  Mechanisms of heart failure in obesity.

Authors:  Imo A Ebong; David C Goff; Carlos J Rodriguez; Haiying Chen; Alain G Bertoni
Journal:  Obes Res Clin Pract       Date:  2014-01-06       Impact factor: 2.288

7.  Myristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties.

Authors:  Sarah Brice Russo; Rotem Tidhar; Anthony H Futerman; L Ashley Cowart
Journal:  J Biol Chem       Date:  2013-03-25       Impact factor: 5.157

8.  Erythrocyte very long-chain saturated fatty acids associated with lower risk of incident sudden cardiac arrest.

Authors:  Rozenn N Lemaitre; Irena B King; Kenneth Rice; Barbara McKnight; Nona Sotoodehnia; Thomas D Rea; Catherine O Johnson; Trivellore E Raghunathan; Leonard A Cobb; Dariush Mozaffarian; David S Siscovick
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-07-21       Impact factor: 4.006

9.  Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview.

Authors:  Jessica S Ross; Sarah B Russo; Georgia C Chavis; Lauren A Cowart
Journal:  Clin Lipidol       Date:  2017-01-18

10.  Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.

Authors:  Megha H Talati; Evan L Brittain; Joshua P Fessel; Niki Penner; James Atkinson; Mitch Funke; Carrie Grueter; W Gray Jerome; Michael Freeman; John H Newman; James West; Anna R Hemnes
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.